Enhancing the action of rituximab by adding fresh frozen plasma for the treatment of fludarabine refractory chronic lymphocytic leukemia

International Journal of Cancer

Volumn 128, Issue 9, 2011, Pages 2192-2201

  Xu, Wei ^a   Miao, Kou Rong ^a   Zhu, Dan Xia ^a   Fang, Cheng ^a   Zhu, Hua Yuan ^a   Dong, Hua Jie ^a   Wang, Dong Mei ^a   Wu, Yu Jie ^a   Qiao, Chun ^a   Li, Jian Yong ^a  

^a NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chronic lymphocytic leukemia; Fresh frozen plasma; Rituximab; Salvage therapy

Indexed keywords

ALLOPURINOL; CD38 ANTIGEN; FLUDARABINE; FRESH FROZEN PLASMA; IMMUNOGLOBULIN HEAVY CHAIN; IMMUNOGLOBULIN HEAVY CHAIN VARIABLE REGION; PROTEIN KINASE ZAP 70; PROTEIN P53; RITUXIMAB; UNCLASSIFIED DRUG;

ADULT; AGED; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; CHILL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL ARTICLE; COMPLEMENT DEPENDENT CYTOTOXICITY; CYTOPENIA; DIZZINESS; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; FOLLOW UP; GENE MUTATION; HUMAN; HUMAN CELL; INFECTION; LEUKEMIA REMISSION; MALE; MINIMAL RESIDUAL DISEASE; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUMOR LYSIS SYNDROME;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MALE; MIDDLE AGED; PLASMA; SALVAGE THERAPY; VIDARABINE;

EID: 79952462585     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.25560     Document Type: Article

References (33)

1. Leporrier M. Role of fludarabine as monotherapy in the treatment of chronic lymphocytic leukemia. Hematol J 2004; 5(suppl 1):S10-9.
2. Cheson BD, Leonard JP. Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 2008;359:613-26.
3. Byrd JC, Murphy T, Howard RS, Lucas MS, Goodrich A, Park K, Pearson M, Waselenko JK, Ling G, Grever MR, Grillo- Lopez AJ, Rosenberg J, et al. Rituximab using a thrice weekly dosing schedule in B-cell chronic lymphocytic leukemia and small lymphocytic lymphoma demonstrates clinical activity and acceptable toxicity. J Clin Oncol 2001;19:2153-64. (Pubitemid 32366969)
4. Huhn D, von Schilling C, Wilhelm M, Ho AD, Hallek M, Kuse R, Knauf W, Riedel U, Hinke A, Srock S, Serke S, Peschel C, et al. German Chronic Lymphocytic Leukemia Study Group. Rituximab therapy of patients with B-cell chronic lymphocytic leukemia. Blood 2001;98:1326-31.
5. O'Brien SM, Kantarjian H, Thomas DA, Giles FJ, Freireich EJ, Cortes J, Lerner S, Keating MJ. Rituximab dose-escalation trial in chronic lymphocytic leukemia. J Clin Oncol 2001;19:2165-70. (Pubitemid 32366970)
6. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001; 98:3383-9.
7. Varga L, Czink E, Miszlai Z, Pálóczi K, Bányai A, Szegedi G, Füst G. Low activity of the classical complement pathway predicts short survival of patients with chronic lymphocytic leukaemia. Clin Exp Immunol 1995;99:112-6.
8. Schlesinger M, Broman I, Lugassy G. The complement system is defective in chronic lymphatic leukemia patients and in their healthy relatives. Leukemia 1996;10:1509-13. (Pubitemid 26290334)
9. Klepfish A, Rachmilewitz EA, Kotsianidis I, Patchenko P, Schattner A. Adding fresh frozen plasma to rituximab for the treatment of patients with refractory advanced CLL. QJM 2008;101:737-40.
10. Xu W, Li JY, Miao KR, Hong M, Qiao C, Wu YJ, Fan L, Liu P. Rituximab combining with fresh frozen plasma for the treatment of patients with refractory advanced CLL. Blood (ASH Annual Meeting Abstracts) 2009;114: Abstract 3450.
11. Cheson BD, Bennett JM, Grever M, Kay N, Keating MJ, O'Brien S, Rai KR. National Cancer Institute-sponsored Working Group guidelines for chronic lymphocytic leukemia: revised guidelines for diagnosis and treatment. Blood 1996;87:4990-7. (Pubitemid 26189840)
12. Binet JL, Auquier A, Dighiero G, Chastang C, Piguet H, Goasguen J, Vaugier G, Potron G, Colona P, Oberling F, Thomas M, Tchernia G, et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981;48:198-206. (Pubitemid 11064396)
13. Chen LJ, Zhang YP, Zheng WJ, Wu YJ, Qiao C, Fan L, Xu W, Li JY. Distinctive IgVH gene segments usage and mutation status in Chinese patients with chronic lymphocytic leukemia. Leuk Res 2008;32:1491-8.
14. Rossi D, Cerri M, Deambrogi C, Sozzi E, Cresta S, Rasi S, De Paoli L, Spina V, Gattei V, Capello D, Forconi F, Lauria F, et al. The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness. Clin Cancer Res 2009; 15:995-1004.
15. Xu W, Li JY, Wu YJ, Yu H, Shen QD, Tian T, Li L, Qiu HX. CD38 as a prognostic factor in Chinese patients with chronic lymphocytic leukaemia. Leuk Res 2009;33:237-43.
16. Qiu HX, Xu W, Cao XS, Zhou M, Shen YF, Xu YL, Sun XM, Liu Q, Wang R, Qiu HR, Wang JS, Li JY. Cytogenetic characterisation in Chinese patients with chronic lymphocytic leukemia: a prospective, multicenter study on 143 cases analysed with interphase fluorescence in situ hybridisation. Leuk Lymphoma 2008; 49:1887-92.
17. Döhner H, Stilgenbauer S, Benner A, Leupolt E, Kröber A, Bullinger L, Döhner K, Bentz M, Lichter P. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343:1910-6. (Pubitemid 32064784)
18. Rawstron AC, Villamor N, Ritgen M, Böttcher S, Ghia P, Zehnder JL, Lozanski G, Colomer D, Moreno C, Geuna M, Evans PA, Natkunam Y, et al. International standardized approach for flow cytometric residual disease monitoring in chronic lymphocytic leukaemia. Leukemia 2007;21:956-64. (Pubitemid 46672072)
19. McLaughlin P, Grillo-López AJ, Link BK, Levy R, Czuczman MS, Williams ME, Heyman MR, Bence-Bruckler I, White CA, Cabanillas F, Jain V, Ho AD, et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 1998;16:2825-33. (Pubitemid 28363048)
20. Nguyen DT, Amess JA, Doughty H, Hendry L, Diamond LW. IDEC-C2B8 anti- CD20 (rituximab) immunotherapy in patients with low-grade non-Hodgkin's lymphoma and lymphoproliferative disorders: evaluation of response on 48 patients. Eur J Haematol 1999;62:76-82. (Pubitemid 29071265)
21. Winkler U, Jensen M, Manzke O, Schulz H, Diehl V, Engert A. Cytokine-release syndrome in patients with B-cell chronic lymphocytic leukemia and high lymphocyte counts after treatment with an anti-CD20 monoclonal antibody (rituximab, IDECC2B8). Blood 1999;94:2217-24. (Pubitemid 29467667)
22. Ladetto M, Bergui L, Ricca I, Campana S, Pileri A, Tarella C. Rituximab anti-CD20 monoclonal antibody induces marked but transient reductions of peripheral blood lymphocytes in chronic lymphocytic leukaemia patients. Med Oncol 2000;17:203-10. (Pubitemid 30657500)
23. Hainsworth JD, Litchy S, Barton JH, Houston GA, Hermann RC, Bradof JE, Greco FA; Minnie Pearl Cancer Research Network. Single-agent rituximab as firstline and maintenance treatment for patients with chronic lymphocytic leukemia or small lymphocytic lymphoma: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol 2003;21: 1746-51. (Pubitemid 46638587)
24. Itala M, Geisler CH, Kimby E, Juvonen E, Tjonnfjord G, Karlsson K, Remes K. Standard-dose anti-CD20 antibody rituximab has efficacy in chronic lymphocytic leukaemia: results from a Nordic multicentre study. Eur J Haematol 2002;69:129-34. (Pubitemid 35335149)
25. Golay J, Lazzari M, Facchinetti V, Bernasconi S, Borleri G, Barbui T, Rambaldi A, Introna M. CD20 levels determine the in vitro susceptibility to rituximab and complement of B-cell chronic lymphocytic leukemia: further regulation by CD55 and CD59. Blood 2001;98:3383-9.
26. Manches O, Lui G, Chaperot L, Gressin R, Molens JP, Jacob MC, Sotto JJ, Leroux D, Bensa JC, Plumas J. In vitro mechanisms of action of rituximab on primary non- Hodgkin lymphomas. Blood 2003;101: 949-54.
27. Golay J, Zaffaroni L, Vaccari T, Lazzari M, Borleri GM, Bernasconi S, Tedesco F, Rambaldi A, Introna M. Biologic response of B lymphoma cells to anti-CD20 monoclonal antibody rituximab in vitro: CD55 and CD59 regulate complement-mediated cell lysis. Blood 2000;95: 3900-8. (Pubitemid 30412866)
28. Taylor RP, Lindorfer MA. Immunotherapeutic mechanisms of anti- CD20 monoclonal antibodies. Curr Opin Immunol 2008;20:444-9.
29. van Meerten T, van Rijn RS, Hol S, Hagenbeek A, Ebeling SB. Complement-induced cell death by rituximab depends on CD20 expression level and acts complementary to antibody-dependent cellular cytotoxicity. Clin Cancer Res 2006;12:4027-35. (Pubitemid 44078090)
30. Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS. CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma. Leuk Lymphoma 2007;48:2424-36. (Pubitemid 350253475)
31. Miszlai Z, Czink E, Varga L, Paloczi K, Szegedi G, Fust G, Hollan SR. Repressed classical complement pathway activities and clinical correlations in chronic lymphocytic leukaemia. Acta Med Hung 1986;43:389-95.
32. Fust G, Czink E, Minh D, Miszlay Z, Varga L, Hollán SR. Depressed classical complement pathway activities in chronic lymphocytic leukaemia. Clin Exp Immunol 1985;60:489-95. (Pubitemid 15021349)
33. O'Brien S, Kantarjian H, Beran M, Smith T, Koller C, Estey E, Robertson LE, Lerner S, Keating M. Results of fludarabine and prednisone therapy in 264 patients with chronic lymphocytic leukemia with multivariate analysis-derived prognostic model for response to treatment. Blood 1993;82:1695-700. (Pubitemid 23278758)